Table 2.
Maximal responses and EC50 values for 5-HT-induced contraction of mesenteric rings from ob/ob and Lean mice
| Treatment | ob/ob mice | Lean mice | ||
|---|---|---|---|---|
| Max. response [g tension·(mg tissue)−1] | −log EC50 | Max. response [g tension·(mg tissue)−1] | −log EC50 | |
| Untreated | 4.61 ± 0.38 (12)‡ | 7.17 ± 0.02 (12)‡ | 2.85 ± 0.22 (12) | 6.94 ± 0.04 (12) |
| L-NNA (10−4 M) | 5.02 ± 0.44 (5) | 7.19 ± 0.10 (5) | 3.33 ± 0.27 (5) | 7.13 ± 0.04 (5) |
| Indomethacin (10−5 M) | 5.19 ± 1.21 (4) | 7.07 ± 0.05 (4)‡ | 3.04 ± 0.34 (4) | 6.82 ± 0.07 (4) |
| Chelerythrine (10−6 M) | 4.21 ± 0.62 (5) | 7.14 ± 0.08 (5)‡ | 2.78 ± 0.41 (5) | 6.83 ± 0.09 (5) |
| PD98059 (10−5 M) | 4.35 ± 0.41 (5)‡ | 6.87 ± 0.08 (5)* | 2.24 ± 0.46 (5) | 6.58 ± 0.18 (5)† |
| Y27632 (10−7 M) | 2.95 ± 0.24 (5)* | 6.98 ± 0.04 (5)* | 2.86 ± 0.29 (5) | 6.87 ± 0.04 (5) |
| Y27632 (10−6 M) | 1.59 ± 0.21 (5)* | 6.82 ± 0.09 (5)* | 1.29 ± 0.23 (5)† | 6.75 ± 0.07 (5) |
| Y27632 (10−5 M) | 0.91 ± 0.13 (5)* | 6.45 ± 0.03 (5)* | 0.67 ± 0.16 (5)† | 6.40 ± 0.05 (5)† |
| PP1 analogue (10−6 M) | 2.88 ± 0.20 (6)* | 6.98 ± 0.08 (6)* | 3.04 ± 0.14 (6) | 6.81 ± 0.03 (6) |
| Src kinase inhibitor I (10−7 M) | 3.13 ± 0.18 (4) | 6.96 ± 0.04 (4)* | 2.78 ± 0.40 (4) | 6.82 ± 0.05 (4) |
Values are means ± SEM. Number of determinations is shown within parentheses.
*
P < 0.05 versus untreated ob/ob group.
†
P < 0.05 versus untreated Lean group.
‡
P < 0.05 versus corresponding Lean group.
5-HT, 5-hydroxytryptamine; L-NNA, NG-nitro-L-arginine.